K-New Drugs: The Future of Bio Is All Written Here | Kim Seon-ah, Hana Securities Research Center Senior Research Fellow

K-New Drugs, The Future of Bio is All Written Here | Kim Seon-ah, Hana Securities Research Center Senior Research Fellow [Double Up]
Watch on YouTube ↗  |  April 30, 2026 at 01:09  |  22:01  |  3PRO TV (삼프로TV)
Speakers
Kim Seon-ah — Senior Research Fellow, Hana Securities Research Center

Summary

Kim Seon-ah, Senior Research Fellow at Hana Securities Research Center, discusses why Korean biotech has underperformed global biotech and why she still expects medium- to long-term recovery. She highlights gene therapy and novel-platform biotech as the strongest themes, names Alzinomics and ST Pharm as key examples, and points to improved quality among recent and upcoming biotech IPOs. She also notes Curocell's new drug approval and upcoming oncology and diabetes conferences as catalysts, while cautioning that near-term May-June returns are uncertain.

  • Korean biotech lagged due to fewer technology-transfer deals and weak earnings.
  • Gene therapy is seen as the strongest current Korean bio theme.
  • Alzinomics drew attention for human cancer gene-therapy data and a Lilly platform contract.
  • ST Pharm's earnings surprise signals rising clinical-material demand.
  • Recent Korean biotech IPOs have shown stronger returns and better quality.
  • Curocell received a new drug approval that could lift its IPO cohort.
  • May-June medical conferences are near-term data catalysts.
  • The speaker favors a medium- to long-term approach over short-term trading.
Ideas
Kim Seon-ah Senior Research Fellow, Hana Securities Research Center 3:15
Korean biotech set for medium-term recovery.
The Korean biotech sector has underperformed because technology-transfer deals have declined and biotechs have little earnings; its correlation with US biotech has broken, but she expects recovery over the medium to long term. Investors should focus on companies that consistently deliver results and keep development timelines, and she expects new quality IPOs to lead KOSDAQ biotech. She cautions not to expect big near-term May-June returns but sees larger multi-year upside than other sectors.
Korean Biotech KOSDAQ Biotech HIGH
Kim Seon-ah Senior Research Fellow, Hana Securities Research Center 4:44
Oncology is watchable, not a clear trend.
Oncology is not a clean structural trend but remains a must-watch area; near-term interest is driven by major conference data. Within oncology, ADC and gene therapy are methods to watch, though the speaker calls gene therapy the stronger theme.
Oncology LOW
Kim Seon-ah Senior Research Fellow, Hana Securities Research Center 5:24
Gene therapy is strongest Korean bio theme.
Gene therapy is the strongest current theme in Korean bio. She highlights that gene therapy for cancer is almost unprecedented in Korea and Alzinomics produced human data, drawing market attention; new modalities and novel platforms attract big pharma because optimized combinations have been exhausted. The theme can be traded through related Korean gene-therapy biotech.
Korean gene therapy HIGH
Kim Seon-ah Senior Research Fellow, Hana Securities Research Center 7:52
Novel-platform biotech attracts big pharma interest.
Big pharma is increasingly interested in entirely new mechanisms and platforms because AI and existing approaches have largely optimized known combinations. Early-stage companies with novel platforms are receiving market attention even in preclinical or early clinical stages, so the opportunity is in novel-platform biotechs.
Novel-platform biotech MED
Kim Seon-ah Senior Research Fellow, Hana Securities Research Center 8:48
Alzinomics leads Korean cancer gene therapy.
Alzinomics has attracted the most attention in gene therapy. It is a rare Korean cancer gene-therapy case with human data, and it won a Lilly platform-related contract. Successful data also raise expectations that the Lilly-licensed genetic hearing loss indication could develop faster.
276730.KQ HIGH
Kim Seon-ah Senior Research Fellow, Hana Securities Research Center 11:00
ST Pharm earnings surprise signals strong demand.
ST Pharm posted a large operating-profit surprise. For the speaker, a producer surprise means real demand: ST Pharm is making large amounts of clinical trial materials, indicating more clinical projects, and as trials advance, manufacturing volume and revenue should rise, creating a virtuous cycle. This reinforces her confidence in gene therapy.
237690.KQ HIGH
Kim Seon-ah Senior Research Fellow, Hana Securities Research Center 12:04
Quality Korean biotech IPOs offer opportunities.
The speaker sees opportunity in Korean biotech IPOs. 2025 listings have generally delivered better returns and maintain market caps above KRW 500bn; stricter technology-special listing standards since 2022 mean listed companies are higher quality and more likely to survive. Many 2026 IPO candidates also have strong track records, so new IPOs are expected to lead KOSDAQ biotech over the medium term.
Korean biotech IPOs HIGH
Kim Seon-ah Senior Research Fellow, Hana Securities Research Center 13:38
Curocell approval may lift IPO cohort.
Curocell received a new drug approval from the Korean regulator, which could improve returns for the 2021-2023 IPO cohort that has been weak. The approval is a positive catalyst for the stock.
372320.KQ MED
Up Next
47:40
Intraday High Broken! Plus Semiconductor Leverage Comes in May | Jang Woojin [Double Check]
3PRO TV (삼프로TV) · Apr 30
1:56:38
[체슬리모닝브리프] Fed 3연속 금리 동결…유가 급등에 혼조 마감 [26/04/30]
Chesley Investment Advisory (체슬리투자자문) · Apr 30
28:00
Tech Earnings Quadkill, Red Button vs Blue Button | Diet TBPN
TBPN · Apr 30
2:41:06
[April 30 #BeforeMarketOpen] Fed, hawkish rate freeze.. New York stock market flat despite oil price surge "Philly Semiconductor up 2.3%" / Alphabet after-hours up 6%
815 Money Talk (815머니톡) · Apr 30
43:21
Samsung Electronics Earnings Announcement...Today is the Real Deal! | Park Byung-chang, Kyobo Securities Asset Management Strategy Department Director [Market Inside]
3PRO TV (삼프로TV) · Apr 30

This 3PRO TV (삼프로TV) video, published April 30, 2026, features Kim Seon-ah discussing Korean Biotech, KOSDAQ Biotech, Oncology, Korean gene therapy, Novel-platform biotech, 276730.KQ, 237690.KQ, Korean biotech IPOs, 372320.KQ. 8 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Kim Seon-ah  · Tickers: Korean Biotech, KOSDAQ Biotech, Oncology, Korean gene therapy, Novel-platform biotech, 276730.KQ, 237690.KQ, Korean biotech IPOs, 372320.KQ